Reviewer's report

Title: Phase II Assessment of Talabostat and Cisplatin in Second-Line Stage IV Melanoma

Version: 2 Date: 20 June 2009

Reviewer: Kevin Kim

Reviewer's report:

Major Compulsory Revisions
None

Minor Essential Revisions
#1. It is more appropriate to move the 6th paragraph of the Discussion section (starting with "The incidence of specific hematologic events was analyzed (Table 6). Few patients....") to the "Safety" subsection under Results section. Most readers look for the myelosuppression toxicity data under the Results section.

#2: In the Abstract (Methods section), the dose of cisplatin was described as 75 mg/m2. Please superscribe 2 in the m2.

Discretionary Revisions
#1: In Table 2, I would recommend that the numbers of PD are omitted altogether.
The percentages in each column do not add up to 100%, which can raise a doubt from readers about the accuracy of the data. In addition, the description of the #s of PD is not necessary in the manuscript.

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: Yes, and I have assessed the statistics in my report.

Declaration of competing interests:
I declare that I have no competing interests.